Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III safety and efficacy trial of SHP465 in adults with Attention-Deficit Hyperactivity Disorder (ADHD)

Next Previous
Trial Profile

A phase III safety and efficacy trial of SHP465 in adults with Attention-Deficit Hyperactivity Disorder (ADHD)

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Jun 2017

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mixed amfetamine salts (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Shire

Most Recent Events

  • 20 Jun 2017 According to a Shire media release, the U.S. FDA has approved MYDAYIS (mixed salts of a single-entity amphetamine product) for patients 13 years and older with Attention Deficit Hyperactivity Disorder (ADHD), based on the results from 16 studies evaluating Mydayis in more than 1,600 subjects, including adolescents (aged 13-17 years) and adults with ADHD.
  • 20 May 2016 New trial record
  • 04 Apr 2016 According to a Shire media release, Shire plans to add these study results to its existing SHP465 data set to submit a Class 2 resubmission for FDA approval of the medicine for treatment of ADHD.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top